UB Paderborn / Katalog / Suche / in CDI

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

Nature (London), 2020-08, Vol.584 (7821), p.479-483

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors

Journal of medicinal chemistry, 2012-11, Vol.55 (22), p.10090-10107

2012

Link zum Volltext

Verfügbarkeit prüfen

Monomeric Targeted Protein Degraders

Journal of medicinal chemistry, 2020-10, Vol.63 (20), p.11330-11361

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a potent and selective Aurora kinase inhibitor

Bioorganic & medicinal chemistry, 2008-09, Vol.18 (17), p.4880-4884

2008

Link zum Volltext

Verfügbarkeit prüfen

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Cancer discovery, 2022-01, Vol.12 (1), p.204-219

2022

Link zum Volltext

Verfügbarkeit prüfen

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Journal of medicinal chemistry, 2015-11, Vol.58 (22), p.8877-8895

2015

Link zum Volltext

Verfügbarkeit prüfen

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

Bioorganic & medicinal chemistry, 2008-10, Vol.18 (19), p.5186-5189

2008

Link zum Volltext

Verfügbarkeit prüfen

Optimization of globomycin analogs as novel gram-negative antibiotics

Bioorganic & medicinal chemistry letters, 2020-10, Vol.30 (20), p.127419-127419, Article 127419

2020

Link zum Volltext

Verfügbarkeit prüfen

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

Bioorganic & medicinal chemistry letters, 2016-01, Vol.26 (2), p.534-539

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Bioorganic & medicinal chemistry letters, 2019-06, Vol.29 (12), p.1522-1531

2019

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Journal of medicinal chemistry, 2014-12, Vol.57 (23), p.10176-10191

2014

Link zum Volltext

Verfügbarkeit prüfen

Lipid Tales: Optimizing Arylomycin Membrane Anchors

ACS medicinal chemistry letters, 2023-11, Vol.14 (11), p.1524-1530

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

Journal of medicinal chemistry, 2016-10, Vol.59 (19), p.9080-9093

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2

Journal of medicinal chemistry, 2012-07, Vol.55 (13), p.6176-6193

2012

Link zum Volltext

Verfügbarkeit prüfen

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR

ACS medicinal chemistry letters, 2016-01, Vol.7 (1), p.100-104

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye

ACS medicinal chemistry letters, 2012-03, Vol.3 (3), p.203-206

2012

Link zum Volltext

Verfügbarkeit prüfen

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Journal of medicinal chemistry, 2016-03, Vol.59 (6), p.2848-2848

2016

Link zum Volltext

Verfügbarkeit prüfen

2-Aminobenzimidazoles as potent Aurora kinase inhibitors

Bioorganic & medicinal chemistry letters, 2009-09, Vol.19 (17), p.5158-5161

2009

Link zum Volltext

Verfügbarkeit prüfen

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.307-310

2011

Link zum Volltext

Verfügbarkeit prüfen

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

Bioorganic & medicinal chemistry, 2008-10, Vol.18 (20), p.5648-5652

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

Bioorganic & medicinal chemistry letters, 2010-09, Vol.20 (17), p.5269-5273

2010

Link zum Volltext

Verfügbarkeit prüfen

Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

Acta crystallographica. Section F, Structural biology and crystallization communications, 2008-08, Vol.64 (8), p.686-691

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1735: Discovery of novel and selective reversible inhibitors of EGFR containing the T790M drug resistance mutation with activity in vitro and in vivo

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1735-1735

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

Monomeric Targeted Protein Degraders

Discovery of a potent and selective Aurora kinase inhibitor

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

Optimization of globomycin analogs as novel gram-negative antibiotics

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Lipid Tales: Optimizing Arylomycin Membrane Anchors

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

2-Aminobenzimidazoles as potent Aurora kinase inhibitors

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

Abstract 1735: Discovery of novel and selective reversible inhibitors of EGFR containing the T790M drug resistance mutation with activity in vitro and in vivo

Suchergebnisse filtern